Posted by AGORACOM-JC
at 8:09 AM on Tuesday, January 26th, 2021
Subsidiary, Health Gauge, successfully displayed its proof-of-concept deployment in a study funded by The Bill and Melinda Gates Foundation, further validating its technology.
Health Gauge was invited in 2019 to participate, as the sole technology provider, in a Bill and Melinda Gates Foundation funded initiative with ICDDR , B (the International Centre for Diarrhoeal Disease Research of Bangladesh) on a research project to study ways to reduce pregnancy complications and mortality, by making healthcare more accessible using wearable solutions.
January 20, 2021 – AI/ML Innovations Inc. (CNSX :AIML.CN ) (OTC:FIRZF) , a company focused on acquiring and furthering Artificial Intelligence/Machine Learning technologies that address urgent societal needs, announces that its subsidiary, Health Gauge, successfully displayed its proof-of-concept deployment in a study funded by The Bill and Melinda Gates Foundation, further validating its technology. Health Gauge was invited in 2019 to participate, as the sole technology provider, in a Bill and Melinda Gates Foundation funded initiative with ICDDR , B (the International Centre for Diarrhoeal Disease Research of Bangladesh) on a research project to study ways to reduce pregnancy complications and mortality, by making healthcare more accessible using wearable solutions. Health Gauge was invited to participate in this study as a result of ICDDR,B’s learning of Health Gauge’s break-through solution in digital pulse and ECG analysis, using simple, affordable, and quality digital signal capture. For this study, Health Gauge’s personal health monitoring solution, including its wearable device, smart phone app, and AI-driven cloud processing platform was used, in conjunction with the support of community-based health service providers.
Conclusion
Studies such as this validate the proof-of-concept of Health Gauge’s products, and show the vast and varied commercial opportunities available within Health Gauge’s bespoke business model. It speaks to the merits and importance of how Health Gauge’s latest generation solutions can help solve important community health problems, in affordable ways, while readily fitting into existing managed care programs – anywhere. Physicians, other healthcare professionals, and individuals can apply and adapt the Health Gauge solution to a number of different health conditions and settings for personal health monitoring and management – showing the larger value of Health Gauge’s device and applications.
Blood pressure related pregnancy maladies are of concern globally, and a leading cause of death amongst pregnant women. Health Gauge’s products have both the ability and opportunity to capitalize on this critical women’s health issue, while providing an invaluable service that has a direct impact on health outcomes.
Background
The study, which commenced in 2019, focused on serving pregnant women who were at risk of developing eclampsia, a hypertension-related significant health risk. Hypertensive disorders of pregnancy (HDP) are extremely dangerous to both the mother and child, and are in fact one of the three leading causes of maternal death worldwide. While hypertension complicates 10% of all pregnancies and is responsible for 14% for all maternal deaths globally, in the developing world it is of even greater concern where mortality rates can be as high as 20%.
Posted by AGORACOM
at 11:33 AM on Monday, January 25th, 2021
(MRBL: CSE) (MRBLF: OTC) (2V0: FSE)
www.mymarble.ca
Why Marble?
Revolutionary fintech company utilizing the power of AI technology to help Canadians manage debt, build credit and budget.
Provides users:
Expert budgeting insights
Consumer proposal-exiting guidance
AI-powered credit boosting intelligence
Financial literacy
Robust B2B and B2C offerings.
A trusted fintech provider for businesses to maximize their customers credit profile.
Servicing a previously underserved subprime Canadian market
Strong Insiders/Management Ownership: 35%
What Exactly Does Marble Do?
‘MyMarble’ offers very specific, personalized financial recommendations about when to pay bills, how to prioritize debt management decisions and offers, tracks and highlights personalized data insights.
‘MyMarble’ through its suite of products offers innovative structured credit product solutions:
The MyMarble Ecosystem obtains leads from a number of tier one Canadian fintech companies which are funnelled accordingly due to a detailed needs analysis.
Did You Know 12 Million Canadians Are Below A Prime Credit Rating?
According to MNP (October 2020) , almost 50% of Canadians are living paycheque to paycheque and based on statistics from Statistics Canada’s Household Sector Credit Market Summary (June 2020), for every dollar of disposable income, Canadians carry a $1.77 of debt. Additionally, Canada is a credit-based economy and financial literacy and good credit score is a major determinant to Financial Inclusion.
What Problem Does That Pose To Individuals Seeking Credit?
The Marble Model
How Marble Acquires and Converts Customers
Benefits of This World Class, AI-Powered Platform:
Expert AI Insights and Real-Time Recommendations
Comprehensive monthly reporting provides expert insights to guide the best course of action to manage budgets effectively
Data-Driven Credit Score Improvement Solution
Marble’s Score-Up AI insights suggests steps which will make the biggest positive impact on credit scores using industry-leading monitoring and point deduction technology.
In a recent Personal Finance Sentiments Survey conducted by Marble, approximately 70% of the respondents commented that they were embarrassed by their credit score, proving a willingness to improve their credit to an acceptable mainstream banking level.
In addition, a similar number of the same respondents identified having over $100 in disposable income each month, confirming Score-Up Lite’s affordability to people that could benefit from it.
Specialist Curated Financial Literacy Platform
The company’s Maestro Financial Literacy education platform has been designed and developed by personal finance experts with decades of experience within the industry.
Sustainable Consumer Proposal Exit solution
One of the only companies in Canada that specializes in exiting consumer proposals in a safe, fair and ethical way.
What Does The Company’s Financial Future Look Like?
Posted by AGORACOM-JC
at 7:55 AM on Monday, January 25th, 2021
Received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO.
MONTREAL , Jan. 25, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO. “Redesca™ has a long and strong history of safety and efficacy with more than 8 years of proven in-market data internationally. Redesca™ will be available across Canada and Valeo intends to pursue discussions for the inclusion of Redesca on all other provincial formularies. Valeo is planning to launch Redesca™ during the first half of 2021.”
In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWHs are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.
Posted by AGORACOM-JC
at 7:49 AM on Monday, January 25th, 2021
Announced a partnership agreement with BOOK YOUR STADIUM ( www.bookyourstadium.com ) to deliver ‘one-of-a-kind’ AR experiences from historical soccer clubs in LaLiga ( Spain ) to fans around the world.
The clubs which BOOK YOUR STADIUM is currently offering in the platform are REAL MADRIDCF , REAL SOCIEDAD CF , REAL VALLADOLID CF, VALENCIA CF, ATHLETIC CLUB , CA OSASUNA , REAL BETIS BALOMPIÉ, and RC CELTA .
Throughout 2021, several national and international clubs are expected to join the platform.
VANCOUVER, BC and ERIE, Pa. , Jan. 25, 2020 – ImagineAR (IP:CSE) (IPNFF:OTCQB) an Augmented Reality company that enables sports teams, entertainers, brands and businesses to instantly create immersive global mobile phone AR campaigns, is excited to announce a partnership agreement with BOOK YOUR STADIUM ( www.bookyourstadium.com ) to deliver ‘one-of-a-kind’ AR experiences from historical soccer clubs in LaLiga ( Spain ) to fans around the world. The clubs which BOOK YOUR STADIUM is currently offering in the platform are REAL MADRIDCF , REAL SOCIEDAD CF , REAL VALLADOLID CF, VALENCIA CF, ATHLETIC CLUB , CA OSASUNA , REAL BETIS BALOMPIÉ, and RC CELTA . Throughout 2021, several national and international clubs are expected to join the platform.
Joaquín Martínez, CEO of BOOK YOUR STADIUM , states: ” We have developed a revolutionary online e-commerce fan engagement site and incorporated ‘best of breed’ innovative digital products. ImagineAR is a leader for sports fan AR engagement and we are going to partner on unique fan AR immersive experiences featuring top LaLiga soccer club players. Additionally, we are now an authorized ImagineAR partner to market their SDK platform to LaLiga clubs for integration into their existing mobile apps which are used by tens of millions of fans around the world.”
BOOK YOUR STADIUM ( www.bookyourstadium.com ), currently available in Spanish, is expected to be available in English in February 2021 and expand globally. Initially, soccer fans can choose from over 200 experiences, adapted to the current health restrictions, to select from historical clubs in LaLiga. Some examples of experiences available include: access to virtual match experiences with exclusive content and games, e-sports matches with football players, Immersive AR experiences, virtual autographs, original match day events, or enjoy club lunch at home. In addition, there is the option of the SPORTBOX® , a themed gift box full of surprises with selected experiences from some clubs.
Posted by AGORACOM-JC
at 9:36 AM on Friday, January 22nd, 2021
Announced today that the CEO of the Company, Cameron Chell, will be featured on Yahoo Finance.
Segment on Yahoo Finance will focus on Draganfly’s recent announcements in relation to Draganfly’s robust vaccine delivery payload for drone delivery of the COVID-19 vaccine.
Los Angeles, CA, Jan. 22, 2021 —Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“ Draganfly ” or the “ Company ”), an award-winning, industry-leading manufacturer and systems developer, announced today that the CEO of the Company, Cameron Chell, will be featured on Yahoo Finance.
The segment on Yahoo Finance will focus on Draganfly’s recent announcements in relation to Draganfly’s robust vaccine delivery payload for drone delivery of the COVID-19 vaccine.
“We are honored to join Yahoo Finance and discuss Draganfly’s vaccine drone delivery payload system,” said Cameron Chell, CEO Draganfly. “We are eager to develop this payload and service as we can leverage our extensive patent portfolio as well as secure auto-pilot and flight management system to help with the distribution of the vaccine for COVID-19 and beyond.”
Cameron Chell’s segment on Yahoo Finance will air at 1040AM ET on Friday, January 22.
Posted by AGORACOM-JC
at 7:57 AM on Friday, January 22nd, 2021
Announced today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.
This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.
Herzliya, Israel and Calgary, Alberta–(January 22, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the “Company” or “Innocan“), is pleased to announce today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.
This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.
This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan’s CBD-loaded LPT in relevant diseases. These studies follow the results of previous studies that demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection.
The previous study, led by Dr. Ahuva Cern, Senior Researcher in the laboratory of Professor Barenholz at the Hebrew University in Jerusalem, found significant amounts of CBD in the blood and muscles of mice up to 21 days after a single intramuscular injection of CBD using the LPT. The same findings were also demonstrated in rats.
Posted by AGORACOM-JC
at 9:26 AM on Thursday, January 21st, 2021
Selected to provide engineering and development services for a drone-based Air Support Defense System for Integrated Launcher Solutions Inc.
Integrated Launcher Solutions Inc. is a systems development and technical integration services company headquartered in Ontario with operations in Florida, with a vision to continually improve launch, range and space systems for its client base of US defense organizations and contractors.
Draganfly will provide Integrated Launcher Solutions Inc. development and engineering expertise and services for the deployment of a non-lethal 40mm multi-launching system that can be mounted and deployed on drones, robots and other remote or autonomous platforms.
Los Angeles, CA, Jan. 21, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, today announced it has been selected to provide engineering and development services for a drone-based Air Support Defense System for Integrated Launcher Solutions Inc. (“ILS”)
Integrated Launcher Solutions Inc. is a systems development and technical integration services company headquartered in Ontario with operations in Florida, with a vision to continually improve launch, range and space systems for its client base of US defense organizations and contractors.
Draganfly will provide Integrated Launcher Solutions Inc. development and engineering expertise and services for the deployment of a non-lethal 40mm multi-launching system that can be mounted and deployed on drones, robots and other remote or autonomous platforms. The main use case of the launch system is public disturbance management for military and public safety organizations.
“ILS approached Draganfly for this project because we are extremely impressed with their innovation in engineering,” said Greg Sullivan, CEO, Integrated Launcher Solutions. “Our client base requires North American developed and made solutions. Draganfly has the expertise to get this project executed.”
“We are honored at the confidence that Integrated Launcher Solutions has placed with Draganfly in overseeing the development of this very important drone technology,” said Cameron Chell, CEO Draganfly. “I am confident that the Draganfly team will provide the right set of expertise and management to develop the non-lethal ILS Air support Defense System.”
Posted by AGORACOM-JC
at 8:42 AM on Wednesday, January 20th, 2021
Company launches first-ever COVID-safe location-based (LBE) Virtual Reality attractions division “UNCONTAINED” to disrupt the marketplace and fulfill demand from its Family Entertainment Center (FEC) clients.
Immersive Tech is planning for a public listing in the first half of 2021.
Leading immersive experience company builds upon current and past relationships with major companies.
Announcement brings creation of the world’s first-ever free-roam interactive VR franchise attraction available for rapid sale to the global attraction and entertainment marketplace.
VANCOUVER, British Columbia, Jan. 20, 2021 — Victory Square Technologies Inc. (“VST”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) , a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that its portfolio company Immersive Tech (“Company”) has launched a premiere new Location-Based Entertainment (LBE) VR attractions division named UNCONTAINED to capitalize on the growing demand for COVID-safe attractions. UNCONTAINED will be the world’s first free-roam interactive VR franchise attraction, built for a COVID world within shipping containers. The experience will allow for up to six players to roam freely within the container while interacting inside a digital environment as a team while making decisions that help guide and define the story.
Immersive Tech designs, engineers and builds custom technology-driven experiences, whether they facilitate brand integration or are aiming to create the best real life adventure possible. The Company recently announced the creation of three unique entertainment escape rooms custom designed and built for Apex Entertainment’s new location in Virginia Beach VA, USA. The three custom room themes include an underwater submarine adventure, a post-war bunker experience, and an AI-controlled warship gone rogue featuring a race against time and a family-friendly focus.
“UNCONTAINED” leverages the manner of design experience that Immersive Tech has gained and honed over the past four years in creating and launching highly successful interactive escape rooms for Family Entertainment Centers. This is complemented by a fundamental understanding of shipping containers as highlighted in their recent 3-room escape experience for Leaps by Bayer, a Bayer Pharmaceutical company, in 2020.
Tags: small cap, small cap stocks, stocks, telehealth, telemedicine, tsx Posted in Victory Square Technologies Inc. | Comments Off on Victory Square Technologies $VST.ca $VSQTF Portfolio Company, Immersive Tech, Announces the Creation of World’s First #COVID-safe Location-Based Entertainment (LBE) Virtual Reality #VR Division “UNCONTAINED” $DBO.ca $YDX.ca $SEV.ca $NTAR.ca
Posted by AGORACOM-JC
at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight.
Saviuk agreed and gave the following reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease. What does this mean?
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
Hesperidin may help against Covid-19 viral replication
Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.
Now you have it. That’s the Valeo story as it applies to just 2 of their amazing products. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
